Kuypers Dirk R J, Claes Kathleen, Evenepoel P, Maes B, Vanrenterghem Yves
Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.
Drug Metab Dispos. 2004 Dec;32(12):1421-5. doi: 10.1124/dmd.104.001503. Epub 2004 Sep 21.
Tacrolimus is characterized by a highly variable oral bioavailability and narrow therapeutic window. Tacrolimus absorption from the gastrointestinal tract is to a large extent determined by the genotypic, phenotypic, and functional expression of P-glycoprotein and CYP3A in the gut wall and liver. It is disputed whether the gastric emptying rate per se is important for determining oral bioavailability of tacrolimus and whether delayed gastric emptying is clinically relevant for therapeutic drug dosing. We conducted a pharmacokinetic study in 50 renal recipients, measuring simultaneously the rate of gastric emptying using a carbon-14-octanoic acid breath test and quantifying drug exposure by area under the concentration-time curve sampling. Gastric half emptying time (t1/2) significantly correlated with time to reach maximum blood tacrolimus (tmax) concentration (r2 = 0.30; p < 0.0001), whereas the gastric emptying coefficient, reflecting the overall gastric emptying rate, showed a weak inverse correlation with tmax (r2 = 0.14; p = 0.007). The time-dependent rate of gastric emptying strongly correlated with the simultaneously measured blood tacrolimus concentration over the first 4 h after oral drug administration (r2 = 0.96; p < 0.0001). Comparison between patients with and without delayed gastric emptying confirmed that maximum blood tacrolimus concentration was reached significantly more slowly in the former group (tmax, 2 +/- 1 h versus 1.48 +/- 0.68 h; p = 0.04), whereas the extent of tacrolimus absorption was not different. Despite a strong association between gastric emptying rate and the timing of tacrolimus absorption from the gut in stable recipients, gastric emptying rate does not affect the total extent of drug absorption and is not responsible for significant alterations in drug exposure, even in situations of delayed gastric emptying.
他克莫司具有口服生物利用度高度可变且治疗窗狭窄的特点。他克莫司从胃肠道的吸收在很大程度上由肠壁和肝脏中P-糖蛋白和CYP3A的基因型、表型及功能表达所决定。胃排空速率本身对于确定他克莫司的口服生物利用度是否重要,以及胃排空延迟对于治疗药物给药是否具有临床相关性,目前存在争议。我们对50名肾移植受者进行了一项药代动力学研究,使用碳-14-辛酸呼气试验同时测量胃排空速率,并通过浓度-时间曲线下面积采样来量化药物暴露。胃半排空时间(t1/2)与达到他克莫司血药浓度最大值(tmax)的时间显著相关(r2 = 0.30;p < 0.0001),而反映总体胃排空速率的胃排空系数与tmax呈弱负相关(r2 = 0.14;p = 0.007)。口服药物后最初4小时内,胃排空的时间依赖性速率与同时测量的他克莫司血药浓度密切相关(r2 = 0.96;p < 0.0001)。对胃排空延迟和未延迟的患者进行比较证实,前一组达到他克莫司血药浓度最大值的速度明显更慢(tmax,2±1小时对1.48±0.68小时;p = 0.04),而他克莫司的吸收程度并无差异。尽管在稳定的受者中胃排空速率与他克莫司从肠道吸收的时间之间存在密切关联,但胃排空速率并不影响药物吸收的总程度,即使在胃排空延迟的情况下,也不会导致药物暴露的显著改变。